Medication info
Hanwha Rocan Tablet 5/8mg (Rosuvastatin Calcium, Candesartan Cilexetil)

Hanwha Rocan Tablet 5/8mg (Rosuvastatin Calcium, Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Hanwha Pharmaceutical Co., Ltd.
Appearance
Pink, round, film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 202301659 · Approved 2023.05.24 · Insurance code 651602920

Summary

Main use
Improvement of dyslipidemia; treatment and prevention of cardiovascular diseases (including hypertension and heart failure)
Who takes it
Adults · Children
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
○ Candesartan cilexetil - Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. ○ Candesartan cilexetil - Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hanwha Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; treatment and prevention of cardiovascular diseases (including hypertension and heart failure)

  • Essential hypertension
  • heart failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
View approved original text

This medication is only used for patients who need to take candesartan cilexetil and rosuvastatin simultaneously. Candesartan cilexetil is mainly used for patients with essential hypertension and heart failure who either require additional treatment with ACE inhibitors or have decreased tolerability. Rosuvastatin is used as an adjunct in patients with hypercholesterolemia and combined hyperlipidemia when dietary therapy and exercise are insufficient, and it is also helpful for homozygous familial hypercholesterolemia. Additionally, rosuvastatin lowers cholesterol levels, slows the progression of atherosclerosis, and reduces the risk of cardiovascular disease, thereby decreasing the risk of stroke, myocardial infarction, and vascular revascularization. Therefore, this medication is effectively used in the management of hypertension and cardiovascular disease risks.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

○ Candesartan cilexetil - Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. ○ Candesartan cilexetil - Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with an allergic reaction to this medication or with liver function issues, pregnant or breastfeeding women, and those with severe kidney or liver impairment should not take this medication. Patients at high risk for muscle disease or muscle damage should also avoid using this medication, especially when taking high doses. Elderly patients or those with hyperkalemia, weakened liver function, and cardiac or kidney diseases require careful monitoring and regular testing when taking this medication. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur during treatment, consult a physician immediately and, if necessary, check the condition through muscle enzyme tests. Liver function tests should also be performed regularly, and if liver enzyme levels significantly increase, the medication should be discontinued. This medication may interact with other blood pressure medications or specific medications, so if you are taking other medications, it is essential to inform your healthcare provider. Women planning to become pregnant should consult their healthcare provider before taking this medication and use appropriate contraception methods. This medication is not recommended for children as safety and efficacy have not been established. Caution is needed while driving or operating machinery, as dizziness or fatigue may occur. In cases of overdose, appropriate treatment is needed based on symptoms, especially if symptoms like hypotension or dizziness occur, medical help should be sought immediately. Keep this medication out of the reach of children, store it in its original container to prevent misuse.

Side effects

Headache, nasopharyngitis, localized infection, chest discomfort, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, glare, dyspepsia, nausea, increased blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, tooth extraction, orthostatic dizziness, miliaria, periodontitis, inflammation, musculoskeletal pain, neck pain, cataract, increased blood sugar, decreased serum sodium, dizziness, orthostatic dizziness, nausea, vascular edema, low back pain, respiratory infection, asthenia, fever, paresthesia, dyspepsia, gastritis, tachycardia, palpitations, increased creatine kinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, dyspnea, rash, increased sweating, hematuria, cerebral infarction, inflammatory spinal cord disease, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, worsening hypertension, unstable blood pressure, vertigo, adrenal insufficiency, leukopenia, neutropenia, agranulocytosis, hyperkalemia, hyponatremia, hypoglycemia, weakness, hunger, diaphoresis, hand tremor, impaired concentration, convulsions, consciousness disturbance, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorder, decreased libido, amnesia, loss of appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, vascular edema, hypersensitivity reaction, diabetes, constipation, abdominal pain, pancreatitis, rash, urticaria, myopathy, rhabdomyolysis, asthenia, acute renal failure, interstitial lung disease, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia with systemic symptom concomitant drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, depression, sleep disorder, liver failure, cognitive impairment, severe muscular weakness, ocular myasthenia, myalgia, CK elevation, ALT elevation, AST elevation, numbness, sensory disturbance, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramping, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a temperature between 1 and 30 degrees Celsius during storage.

Appearance and packaging

Appearance

Pink, round, film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.